{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T21:33:30Z","timestamp":1786743210799,"version":"build-2736575974"},"reference-count":20,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Many anticancer agents are associated with immediate hypersensitivity reactions, and taxanes are among the most frequently implicated drug class. Although the mechanisms underlying paclitaxel-induced hypersensitivity reactions remain incompletely understood, environmental exposures may influence immune responsiveness. Seasonal variation and associated pollen exposure may modify the risk of paclitaxel-induced hypersensitivity reactions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a retrospective, single-center, Institutional Review Board-approved review of adult patients who received at least one paclitaxel infusion at our institution between November 20, 2023, and December 31, 2024.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 2526 patients included, 554 (22%) experienced a hypersensitivity reaction to paclitaxel. The largest proportion of hypersensitivity reactions occurred during the winter months, with 29% of all hypersensitivity reactions occurring during December, January, and February. In multivariate analysis, however, fall months (September, October, November) were independently associated with increased odds of hypersensitivity to paclitaxel (OR: 1.52; 95% CI: 1.14, 2.02; p=0.029).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Seasonal variation was associated with paclitaxel-induced hypersensitivity reactions, with fall months demonstrating increased risk in adjusted analyses. These findings are exploratory and warrant validation in larger, multicenter datasets.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552261477684","type":"journal-article","created":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T14:56:41Z","timestamp":1786460201000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Seasonal variation and risk of paclitaxel-induced hypersensitivity reactions: A retrospective cohort study"],"prefix":"10.1177","author":[{"given":"Jessica","family":"Bylyku","sequence":"first","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Vicinanza-Rickard","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Timoney","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daria","family":"Chien","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2682-5719","authenticated-orcid":false,"given":"Julia","family":"Blanter","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Zhou","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexia","family":"Iasonos","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0252-8883","authenticated-orcid":false,"given":"Amelia","family":"Chan","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8217-4554","authenticated-orcid":false,"given":"Roisin E","family":"O'Cearbhaill","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center"},{"name":"Weill Cornell Medical College, Department of Medicine, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Autumn","family":"Guyer","sequence":"additional","affiliation":[{"name":"Weill Cornell Medical College, Cornell University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,8,11]]},"reference":[{"key":"e_1_3_3_2_2","article-title":"Management of infusion reactions to systemic anticancer therapy: ESMO clinical practice guidelines","volume":"28","author":"Rosell\u00f3 S","year":"2017","unstructured":"Rosell\u00f3 S, Blasco I, Garc\u00eda Fabregat L, et al. Management of infusion reactions to systemic anticancer therapy: ESMO clinical practice guidelines. Ann Oncol. Jul 1 2017; 28: iv100\u2013iv118.","journal-title":"Ann Oncol. Jul"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2025.02.042"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1053-4296(03)00031-6"},{"key":"e_1_3_3_5_2","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) v6.0 (MedDRA 28.0). 2025. https:\/\/dctd.cancer.gov\/research\/ctep-trials\/for-sites\/adverse-events\/ctcae-v6.pdf."},{"key":"e_1_3_3_6_2","unstructured":"National Cancer Institute. Hypersensitivity. NCI Dictionary of Cancer Terms: U.S. Department of Health and Human Services."},{"key":"e_1_3_3_7_2","unstructured":"National Cancer Institute. Allergic Response. NCI Dictionary of Cancer Terms: U.S. Department of Health and Human Services."},{"key":"e_1_3_3_8_2","unstructured":"Taxol (Paclitaxel). Prescribing Information. Bristol-Myers Squibb 2011. Accessed June 1 2026. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/020262s049lbl.pdf."},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-014-8416-0"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1021\/ja00738a045"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/367593a0"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.2174\/187152009787047761"},{"key":"e_1_3_3_13_2","first-page":"205","article-title":"Taxol reactions","volume":"23","author":"Price KS","year":"2002","unstructured":"Price KS, Castells MC. Taxol reactions. Allergy Asthma Proc May\u2013Jun 2002; 23: 205\u2013208.","journal-title":"Allergy Asthma Proc"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/hr\/uhae346"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2002-19865"},{"key":"e_1_3_3_16_2","unstructured":"National Oceanic and Atmospheric Administration. Infographic: Meteorological and Astronomical Seasons. Accessed June 2 2026. https:\/\/www.noaa.gov\/education\/multimedia\/infographic\/infographic-meteorological-and-astronomical-seasons."},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.18637\/jss.v033.i01"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.18637\/jss.v039.i05"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-19425-7"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12940-015-0057-0"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2006.04.006"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552261477684","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552261477684","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552261477684","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T20:59:11Z","timestamp":1786741151000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552261477684"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,11]]},"references-count":20,"alternative-id":["10.1177\/10781552261477684"],"URL":"https:\/\/doi.org\/10.1177\/10781552261477684","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,11]]},"article-number":"10781552261477684"}}